Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
JT/Torii License Menlo’s Pruritus Candidate for Japan Market
Japan Tobacco and its subsidiary Torii Pharmaceutical signed a licensing accord with Menlo Therapeutics to exclusively develop and commercialize the US biotech’s pruritus drug candidate serlopitant in Japan, the companies said on August 10. Serlopitant, an oral neurokinin-1 (NK-1) receptor…
To read the full story
Related Article
- JT, Torii Ditch Pruritus Candidate Development
June 29, 2018
- Torii Calls Off PII Study of Menlo’s Pruritus Candidate
April 27, 2018
BUSINESS
- Viatris Recalls Sevoflurane Anesthetic over Manufacturing Deviation
August 3, 2026
- Belite Bio Japan Launches Stargardt Disease Awareness Initiative
August 3, 2026
- Otsuka Eyes 3.5 Trillion Yen Sales by 2035 on New Growth Drivers
August 3, 2026
- Daiichi Sankyo Cuts FY2027 Net Profit Outlook on Higher Tax Burden
August 3, 2026
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…